CONNECT WITH US
eCommerce

eCommerce

Protein boom fuels Doctor’s Choice growth: Doubles revenue, bets on 3x production capacity for next growth phase

ET Retail – Ecommerce logo

Published on

Add as a preferred source on Google
Protein boom fuels Doctor’s Choice growth: Doubles revenue, bets on 3x production capacity for next growth phase

Protein boom fuels Doctor’s Choice growth: Doubles revenue, bets on 3x production capacity for next growth phase

Doctor's Choice, founded in 2024, targets revenue growth of Rs 120 crore in FY27 and Rs 300 crore in FY28. The brand is expanding its production capacity significantly to meet increasing demand through online and offline sales channels. Currently generating 80% of their revenue from protein oats, they are also planning to enter international markets.

Bootstrapped FMCG brand Doctor’s Choice is targeting revenue of Rs 120 crore in FY27 and Rs 300 crore in FY28, after doubling its revenue to Rs 60 crore in FY26, as it plans to expand production capacity from 300 metric tonnes to 700–1,000 metric tonnes a month to support rising demand across online and offline channels. “We are scaling almost 2x every year, and the best part is that we are bootstrapped and pumping our own profits back into the company,” Ankit Jha, co-founder, Doctor’s Choice, told ETRetail. Founded in 2024 by Ankit Jha and Nupur Jha, the Gurugram-based brand sells protein oats , protein muesli and peanut butter. It is targeting Rs 300 crore in revenue in FY28, with plans to reinvest profits into scaling the business and entering international markets, particularly the GCC region by February- March. Advt

The brand’s revenue rose from Rs 30 crore in FY25 to Rs 60 crore in FY26. Jha said it had crossed Rs 100 crore in annualised revenue run rate in July, while the full-year FY27 revenue target stands at Rs 120 crore.


Source link
Related Topics:eCommerce

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.